More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...

IBI3030 significantly reduces LDL-c (p<0.01 vs. baseline) and Lp(a), improves oral glucose tolerance (OGTT) (effective even in GLP-1R knockout mice), reduces body weight, and preserves insulin ...

Phase 3 data support use of the oral non-peptide small molecule as potential first-line type 2 diabetes treatment, investigator says.

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

GLP-1 drugs like Ozempic and Wegovy change food cravings and taste preferences—leading to weight loss beyond just reduced appetite.